Immunohistochemical determination of her2 expression in breast cancer from core biopsy specimens: a reliable predictor of her2 status of the whole tumor
- 1 September 2001
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 69 (1) , 13-19
- https://doi.org/10.1023/a:1012281221647
Abstract
HER2 overexpression in breast cancer is associated with a poor prognosis, resistance to endocrine therapy and chemosensitivity to anthracyclines and paclitaxel. Moreover, trastuzumab (HerceptinR)...Keywords
This publication has 31 references indexed in Scilit:
- HER-2/neu Gene Amplification Compared With HER-2/neu Protein Overexpression and Interobserver Reproducibility in Invasive Breast CarcinomaAmerican Journal of Clinical Pathology, 2000
- Role of HER2 gene overexpression in breast carcinomaJournal of Cellular Physiology, 2000
- Assessment of HER2 status in breast cancerEuropean Journal Of Cancer, 2000
- Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancerClinical Therapeutics, 1999
- Her-2/neu as a Predictive Marker of Response to Breast Cancer TherapyBreast Cancer Research and Treatment, 1998
- c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancerEuropean Journal Of Cancer, 1995
- The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 casesBreast Cancer Research and Treatment, 1995
- Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatmentGene, 1995
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerNew England Journal of Medicine, 1994
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987